## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 5.3% in lower entry zone (4.0-10.0%), top quartile (86th pct) cross-sectional ranking. Caution: MRS_5 (-0.1%) diverging from MRS_20, watch for reversal. Momentum building (+0.8% 5-day). Outperforming sector by 8.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($78.39)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. AI-Powered Medical Devices Market Forecast Report 2025-2032: A Projected $59.8 Billion Industry Led by GE HealthCare Technologies, Siemens Healthineers, Philips, Canon Medical Systems, and Fujifilm - ResearchAndMarkets.com**
- Source: Markets Financial Content | 20251209T101400 | Bullish | Relevance: 100%
-  The AI-Powered Medical Devices Market is projected to grow from $15.64 billion in 2024 to $59.84 billion by 2032, expanding at an 18.26% CAGR. This growth is driven by technological integration, expanding adoption in clinical settings, and supportive reimbursement frameworks. The report highlights crucial aspects such as AI's role in device lifecycles, advanced technologies driving innovation, and the importance of cybersecurity and strategic partnerships.

**2. 18,934 Shares in GE HealthCare Technologies Inc. $GEHC Bought by London & Capital Asset Management Ltd**
- Source: MarketBeat | 20251209T131728 | Bullish | Relevance: 99%
-  London & Capital Asset Management Ltd recently acquired 18,934 shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the second quarter, valued at approximately $1.4 million. Several other institutional investors have also adjusted their holdings in GEHC, indicating significant institutional interest. The company recently reported its quarterly earnings, beating analyst estimates, and announced a quarterly dividend.

**3. First Trust Advisors LP Has $61.43 Million Position in GE HealthCare Technologies Inc. $GEHC**
- Source: MarketBeat | 20251208T091252 | Somewhat-Bullish | Relevance: 99%
-  First Trust Advisors LP significantly increased its stake in GE HealthCare Technologies Inc., raising its position by 69.1% to 829,321 shares, valued at $61.43 million. This increase follows GE HealthCare's strong Q2 results, beating EPS and revenue estimates, and aligns with a "Moderate Buy" consensus rating from analysts with an average target price of $86.45. Other institutional investors have also adjusted their holdings in the company.

**4. Guggenheim Capital LLC Purchases 24,087 Shares of GE HealthCare Technologies Inc. $GEHC**
- Source: MarketBeat | 20251206T113353 | Somewhat-Bullish | Relevance: 99%
- Guggenheim Capital LLC increased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 22.3% during the second quarter, buying an additional 24,087 shares and bringing its total holdings to 131,985 shares valued at $9.776 million. Other institutional investors also adjusted their positions in GE HealthCare Technologies, which recently announced a quarterly dividend and reported earnings slightly above consensus estimates. The company's stock shows a 50-day moving average of $75.95 and a 200-day moving average of $74.47, with several analysts maintaining "Buy" or "Hold" ratings.

**5. HSBC Adjusts Price Target on GE Healthcare Technologies to $100 From $87, Maintains Buy Rating**
- Source: marketscreener.com | 20251208T130814 | Bullish | Relevance: 98%
-  HSBC has raised its price target for GE Healthcare Technologies (GEHC) from $87 to $100, while reiterating a "Buy" rating on the stock. This adjustment comes amidst ongoing news about GE HealthCare's strategic developments, including new partnerships and technological advancements in medical imaging and diagnostics. The company continues to declare quarterly dividends and introduces advanced solutions powered by AI and NVIDIA technology.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.9B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 16.8 |
| Current P/E | 18.3 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.8% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 7.4% shows strong absolute momentum above own 20MA. Outperforming sector by 8.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.84), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.29% (CS: 86) | Strong |
| RSI_14 | 63.0 | Neutral |
| MACD Histogram | 0.84 | Bullish |
| vs SMA20 | 1.074x | Above |
| vs SMA50 | 1.093x | Above |
| vs SMA200 | 1.113x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $83.09
- **Stop Loss:** $78.39 (5.7% risk)
- **Target:** $90.14 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 106
- **Position Value:** $8,807.54
- **Portfolio %:** 8.81%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*